RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism Potential Of The Co's TAMP Therapy Platform To Improve Targeted Cancer Drug Treatment Delivery
Portfolio Pulse from Benzinga Newsdesk
RenovoRx (NASDAQ: RNXT) announced the publication of pre-clinical studies that support the efficacy and drug delivery mechanism of its TAMP therapy platform. The studies show that TAMP increases intra-arterial pressure, leading to a 100-fold increase in local tissue concentration of the therapy, potentially improving efficacy, safety, and widening the therapeutic window of drugs. The data was published in the Journal of Vascular Interventional Radiology.
May 21, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx's publication of pre-clinical studies on its TAMP therapy platform demonstrates significant improvements in drug delivery for cancer treatment, potentially increasing the platform's efficacy and safety. This positive development could boost investor confidence and drive the stock price up in the short term.
The publication of pre-clinical studies in a peer-reviewed journal provides strong validation for RenovoRx's TAMP therapy platform. The significant improvement in drug delivery and potential for increased efficacy and safety are likely to be viewed positively by investors, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100